Evaxion A/S vs Innate Pharma
EVAX and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVAX and IPHA compare
Evaxion A/S grew revenue faster over the last twelve months (125% versus −55.2% for Innate Pharma).
Evaxion A/S scores higher on the StockData Score (2 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVAX | IPHA |
|---|---|---|
| Size and price | ||
| Share price | $2.91 | $1.59 |
| Change, 1 year | −54.4% | −30.9% |
| Change, 5 years | −99.0% | −68.3% |
| Beta (5Y) | 1.24 | 0.95 |
| Employees | 45 | 181 |
| StockData Score | ||
| Total score | 2 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 125% (better) | −55.2% |
| Revenue growth, 5Y average | – | −33.6% |
| Profitability | ||
| Operating margin | −123% (better) | −600% |
| Net margin | −102% | – |
| FCF margin | −88.2% (better) | −587% |
| Financial health | ||
| Interest coverage | −2.3× (better) | −17.3× |
| Current ratio | 5.06 (better) | 0.60 |
| Piotroski F-score | 5 | – |
| Ownership | ||
| Held by institutions | 0.38% | 0.21% |
| Held by insiders | 3.5% | 16.2% |
Go deeper
- EVAX stock overview
- EVAX income statement
- EVAX valuation and score
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.